Seaport Therapeutics, Inc.
corporate_fare Company Profile
Seaport Therapeutics, Inc. (NASDAQ:SPTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for SPTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-09, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for SPTX spans 10-Q, 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- GlyphAgo Phase 1 PK Shows 6.8x Bioavailability, 10x Lower Variability
- Seaport Doses First Patient in Phase 2a Trial of GlyphAgo for Anxiety
- Seaport's GlyphAllo Shows No Driving Impairment in Phase 1, Boosting MDD Program
- Seaport Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances
- Seaport Therapeutics Q2 2026: $427M Cash, Pipeline Progress, and $260M Upsized IPO
Short Interest & Short Volume
17.42 days to coverFINRA reported short interest of 3,733,388 shares in SPTX as of the October 30, 2026 settlement, a 0.4% increase from the prior period — about 17.4 days to cover at its recent average daily volume. On November 20, 2026, 73.8% of SPTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.